Updated:
MediVentures
MediVentures is the venture capital arm of the Puetter family office. It started in 2019 as an early-stage investor in digital health ventures and in 2024...
MediVentures
MediVentures is the venture capital arm of the Puetter family office. It started in 2019 as an early-stage investor in digital health ventures and in 2024 began pivoting to investing into VC funds, with capacity for opportunistic co-investments, while continuing to support existing portfolio companies. It promotes future-proof technologies in a sustainable healthcare system.
General information
Firm type
Venture Capital
Year founded
2019
Location
Region
Europe
Country
Germany
City
Iserlohn
Corporate office
Medice Allee 1, 58638 Iserlohn, Germany
Principals
Philipp Große
Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at MediVentures?
Managing Director Philipp Große leads the firm. He operates from the Puetter family office's headquarters in Iserlohn, Germany. The governance structure places final investment authority with the family office, aligning fund commitments and co-investments with the broader family capital strategy.
Does MediVentures participate in fund commitments or only direct deals?
Since announcing its 2024 pivot, the primary strategy is fund commitments. The firm enters LP positions of up to €5 million per fund. It retains the capacity to make opportunistic direct co-investments with the funds it has already backed.
What investment stages does MediVentures typically target?
The firm focuses on funds active at pre-seed, seed, Series A, and Series B. It also evaluates special vehicles for secondary investments and profit-driven impact funds. This stage coverage runs from company formation through early growth.
How does MediVentures source proprietary deal flow?
The firm's sourcing model relies on relationships with established and first-time GPs across the EU, EFTA, and UK. By entering LP positions, MediVentures gains visibility into the underlying portfolio companies, creating a proprietary pipeline for direct co-investments without maintaining a standalone origination team.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: